Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2020

Equity [Abstract]

Schedule of Shares Repurchased

The table below summarizes the shares of our Common Stock we repurchased during 2020 under the program and the cost of the shares received, which were recorded as Treasury Stock. There were no shares repurchased under the program during the three months ended June 30, 2020.

	Six Months Ended June 30, 2020
Number of shares repurchased	719,167
Total cost of shares received	$	272.8

As of June 30, 2020, the Company had $473.1 million which remained available for share repurchases under the program.

The table below summarizes the shares of our Common Stock Sanofi elected to sell, and we elected to purchase, to satisfy Sanofi's funding obligations and the cost of the shares received, which were recorded as Treasury Stock:

	Three Months Ended June 30,			Six Months Ended June 30,
	2020		2019	2020		2019
Libtayo:
Number of shares purchased (by issuing a credit towards the amount owed by Sanofi)	34,050		—	77,677		106,972
Total cost of shares received	$	20.3	—	$	41.7	$	44.0
Dupilumab/REGN3500:
Number of shares purchased (in cash)	86,184		—	171,471		24,143
Total cost of shares received	$	51.5	—	$	93.3	$	10.0

As of June 30, 2020, 279,766 shares of our Common Stock remained available for sale by Sanofi to satisfy its funding obligations with respect to Libtayo development costs and/or Dupilumab/REGN3500 Eligible Investments through September 30, 2020.